Alyeska Investment Group
SYRS

Alyeska Investment Group’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Alyeska Investment Group’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-8,613
Closed -$918K – 607
2020
Q2 		$918K Sell
8,613
-1,387
-14% -$124K 0.01% 407
2020
Q1 		$593K Hold
10,000
– – 0.01% 325
2019
Q4 		$691K Hold
10,000
– – 0.01% 340
2019
Q3 		$1.04M Hold
10,000
– – 0.02% 322
2019
Q2 		$926K Buy
+10,000
New +$696K 0.01% 370

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Alyeska Investment Group's SYRS Position: Q2 2021 in Review

Alyeska Investment Group sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2021, closing a stake of 12,500 shares — an estimated $935K sold.

Alyeska Investment Group first reported a position in SYRS in Q2 2016 and held it in 6 quarters. The position peaked at $2.94M in Q2 2019. 100 funds tracked by Wall St. Rank hold SYRS as of Q2 2021.

  • Alyeska Investment Group reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Alyeska Investment Group sold 12,500 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $935K.
  • Alyeska Investment Group first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2016 and held it in 6 quarters.
  • Alyeska Investment Group's Syros Pharmaceuticals, Inc. Common Stock position peaked at $2.94M in Q2 2019.
  • 100 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on Alyeska Investment Group's 13F filing for Q2 2021, filed 16 Aug 2021.